Climb Bio (CLYM) Amortizatization of Intangibles (2021 - 2026)
Climb Bio (CLYM) posted Amortizatization of Intangibles of $305000.0 for Q1 2026, down 40.31% on a QoQ basis from $511000.0 in Q4 2025, and down 54.41% year-over-year from $669000.0 in Q1 2025.
Climb Bio (CLYM) Amortizatization of Intangibles (2021 - 2026) Analysis & Trends
Climb Bio's Amortizatization of Intangibles history runs 6 years deep, the most recent figure standing at $305000.0 for Q1 2026.
- Quarterly Amortizatization of Intangibles fell 54.41% year-over-year to $305000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.9 million (up 40.13% YoY) and the FY2025 annual result came in at $2.3 million, up 200.4% from the prior year.
- Amortizatization of Intangibles was $305000.0 for Q1 2026 at Climb Bio, down from $511000.0 in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at $753000.0 in Q3 2023 and bottomed at -$193000.0 in Q1 2022.
- A 5-year average of $365250.0 and a median of $445500.0 in 2022 frame the typical range for Amortizatization of Intangibles.
- Annual changes were most pronounced in 2023 — Amortizatization of Intangibles jumped 975.71% — and 2024, when it plunged 87.17%.
- Climb Bio's Amortizatization of Intangibles stood at $400000.0 in 2022, then slipped by 13.5% to $346000.0 in 2023, then jumped by 51.73% to $525000.0 in 2024, then decreased by 2.67% to $511000.0 in 2025, then slumped by 40.31% to $305000.0 in 2026.
- Business Quant data shows CLYM's Amortizatization of Intangibles at $305000.0 in Q1 2026, $511000.0 in Q4 2025, and $523000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 3.22 Mn |
| 10 | Climb Bio | 877.15 Mn | 877.15 Mn | - | 305,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 305,000.00 |
| Mar 31, 2026 | 305,000.00 |
| Dec 31, 2025 | 511,000.00 |
| Dec 31, 2025 | 511,000.00 |
| Sep 30, 2025 | 523,000.00 |
| Sep 30, 2025 | 523,000.00 |
| Jun 30, 2025 | 571,000.00 |
| Jun 30, 2025 | 571,000.00 |
| Mar 31, 2025 | 669,000.00 |
| Mar 31, 2025 | 669,000.00 |
| Dec 31, 2024 | 525,000.00 |
| Dec 31, 2024 | 525,000.00 |
| Sep 30, 2024 | 169,000.00 |
| Sep 30, 2024 | 169,000.00 |
| Mar 31, 2024 | 63,000.00 |
| Mar 31, 2024 | 63,000.00 |
| Dec 31, 2023 | 346,000.00 |
| Dec 31, 2023 | 346,000.00 |
| Sep 30, 2023 | 753,000.00 |
| Sep 30, 2023 | 753,000.00 |